Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of rivaroxaban and enoxaparin in the prevention of recurrent venous thromboembolism
IRCT20201123049469N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rivaroxaban and enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoint: Prevention of recurrent venous thromboembolism. Started Dec 2020; status: completed.
02
Drugs
rivaroxabanenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on IRCT20201123049469N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201123049469N1.